100% satisfaction guarantee Immediately available after payment Both online and in PDF No strings attached
logo-home
FA-MA107 Polyfarmacie Samenvatting Tentamenstof $12.33
Add to cart

Summary

FA-MA107 Polyfarmacie Samenvatting Tentamenstof

2 reviews
 62 views  2 purchases
  • Course
  • Institution

In deze samenvatting van FA-MA107 Polyfarmacie zijn de 8 casussen omschreven die in de cursus aanbod gekomen zijn. Bij het schriftelijk tentamen wordt er op een zelfde manier van je gevraagd om een casus uit te werken. Tijdens het mondeling komen deze casussen aanbod. Er wordt een vervolgvraag gevr...

[Show more]

Preview 4 out of 104  pages

  • February 8, 2022
  • 104
  • 2021/2022
  • Summary

2  reviews

review-writer-avatar

By: marwa121215 • 1 year ago

review-writer-avatar

By: ihds • 1 year ago

avatar-seller
FA-MA107 Polyfarmacie



M. de Leeuw



FA-MA107
Polyfarmacie
Samenvatting




1

,FA-MA107 Polyfarmacie M. de Leeuw



Inhoud
Leerdoelen ..........................................................................................................................................5
Casus 1; Een vrouw (40 jr) met psychische problematiek .......................................................................6
Casus 2 + 8b; Een man (71 jr.) met atriumfibrilleren ............................................................................ 10
Casus 3; Een vrouw (49 jr.) met DM2 en neuropathische pijn .............................................................. 14
Casus 4; Een man (75 jr.) met Parkinson & trombose .......................................................................... 20
Casus 5; Een vrouw (87 jr.) met Parkinson en verwardheid.................................................................. 26
Casus 6; Een man (63 jr.) met hartfalen na een myocard infarct .......................................................... 32
Casus 7; Een man (70 jr.) met COPD, depressie en beroerte................................................................. 37
Casus 8a; Een vrouw (64 jr.) met de ziekte van Crohn.......................................................................... 44
Jicht (Gout) ....................................................................................................................................... 49
Pathofysiologie van jichtartritis................................................................................................................. 49
Symptomen van jicht................................................................................................................................. 49
Beleid bij jicht ............................................................................................................................................ 49
Acute aanval .......................................................................................................................................... 50
Onderhoudsbehandeling....................................................................................................................... 50
Werkingsmechanismen & veiligheid ......................................................................................................... 51
Prednisolon ........................................................................................................................................... 51
NSAID’s (hoog gedoseerd)..................................................................................................................... 51
Colchicine .............................................................................................................................................. 52
Allopurinol ............................................................................................................................................. 52
Benzbromaron ....................................................................................................................................... 52
Febuxostat ............................................................................................................................................. 53
Inflammatoire darmaandoeningen (IBD) ............................................................................................ 54
Colitis Ulcerosa vs. Ziekte van Crohn ........................................................................................................ 54
Pathogenese en pathofysiologie ............................................................................................................... 55
Collitis Ulcerosa ..................................................................................................................................... 56
De ziekte van Crohn .............................................................................................................................. 57
Medicamenteus beleid.............................................................................................................................. 58
Inductiefase ........................................................................................................................................... 58
Onderhoudsfase .................................................................................................................................... 59
Step up vs top down .............................................................................................................................. 60
Zwangere vrouw met IBD ...................................................................................................................... 61
Chirurgische opties ................................................................................................................................ 61
Personalized medicine .......................................................................................................................... 61
Geneesmiddelen ....................................................................................................................................... 62
Mesalazine(analogen) / aminosalicylaten ............................................................................................. 62
Corticosteroïden .................................................................................................................................... 64
Thiopurines............................................................................................................................................ 64
Methotrexaat ........................................................................................................................................ 65
Ciclosporine ........................................................................................................................................... 65
Tacrolimus ............................................................................................................................................. 65

2

,FA-MA107 Polyfarmacie M. de Leeuw


TNF-α-remmers ..................................................................................................................................... 65
Vedolizumab.......................................................................................................................................... 66
Ustekinumab ......................................................................................................................................... 66
Tofacitnib............................................................................................................................................... 66
Geneesmiddelgebruik bij ouderen; Startcriteria.................................................................................. 67
Geneesmiddelgebruik bij ouderen; Stopcriteria .................................................................................. 69
Richtlijn Angststoornissen.................................................................................................................. 72
NHG-standaard Angst 2019 ....................................................................................................................... 72
Richtlijnendatabasen 2020; paniekstoornis .............................................................................................. 72
Nervositeit/ Spanning................................................................................................................................ 72
Richtlijn; Anticonceptie...................................................................................................................... 73
NHG-standaard anticonceptie ................................................................................................................... 73
Richtlijn; Astma ................................................................................................................................. 74
Richtlijn; Atriumfibrilleren ................................................................................................................. 76
Antitrombotische behandeling ................................................................................................................. 76
Frequentiecontrole ................................................................................................................................... 76
Ritmecontrole............................................................................................................................................ 77
Richtlijn; Cardiovasculair Risicomanagement ...................................................................................... 78
Leefstijladviezen ........................................................................................................................................ 78
Lipiden; cholesterolverlagende therapie .................................................................................................. 78
Hypertensie; Bloeddruk verlagende therapie ........................................................................................... 79
Richtlijn; COPD .................................................................................................................................. 81
Onderhoudsmedicatie............................................................................................................................... 81
Richtlijn; Depressie ............................................................................................................................ 82
Richtlijn; Diabetes Mellitus type 2 ...................................................................................................... 83
Niet zeer hoog risico patiënten ................................................................................................................. 83
Zeer hoog risico patiënten ........................................................................................................................ 83
Streefwaarden HbA1c................................................................................................................................. 83
Bloedglucose verlagende middelen .......................................................................................................... 84
Richtlijn; Droge ogen ......................................................................................................................... 86
Richtlijn; Eczeem ............................................................................................................................... 87
NHG-Standaard eczeem 2014 ................................................................................................................... 87
Richtlijn; Hartfalen ............................................................................................................................ 88
Contra-indicatie NSAID .............................................................................................................................. 88
Richtlijn; Incontinentie bij vrouwen.................................................................................................... 89
Medicamenteus beleid stressincontinentie .............................................................................................. 89
Medicamenteus beleid bij urgency-incontinentie .................................................................................... 89
Richtlijn; Maagklachten & maagbescherming ..................................................................................... 91
NHG-Standaard Maagklachten 2021......................................................................................................... 91
Maagbescherming (fk) .............................................................................................................................. 92
Richtlijn; Mictieklachten bij mannen .................................................................................................. 93
Beleid bij aspecifieke mictieklachten ........................................................................................................ 93
Bij incontinentie als voornaamste klacht .................................................................................................. 93
Bij nycturie als voornaamste klacht .......................................................................................................... 93

3

, FA-MA107 Polyfarmacie M. de Leeuw


PDE-5-remmers ......................................................................................................................................... 93
5-alfareductaseremmers ........................................................................................................................... 93
Richtlijn; Neuropathische pijn ............................................................................................................ 94
Acute nociceptieve pijn ............................................................................................................................. 94
Neuropathische pijn .................................................................................................................................. 94
Richtlijn; Chronische Nierschade ........................................................................................................ 96
Richtlijn; Obstipatie ........................................................................................................................... 97
Richtlijn; Osteoporose / fractuurpreventie ......................................................................................... 97
Calcium ...................................................................................................................................................... 97
Vitamine D ................................................................................................................................................. 97
Bifosfonaten .............................................................................................................................................. 98
Beleid na 5 jaar bisfosfonaten ............................................................................................................... 98
Richtlijn; Parkinson ............................................................................................................................ 98
Ongecompliceerde fase............................................................................................................................. 98
Gecompliceerde fase ................................................................................................................................. 99
Richtlijn; Slaapproblemen en slaapmiddelen .................................................................................... 100
NHG-standaard Slaapproblemen en slaapmiddelen 2014 ...................................................................... 100
Richtlijn; Urineweginfecties ............................................................................................................. 101
Werkingsmechanismen en bijwerkingen antibiotica .............................................................................. 103




4

The benefits of buying summaries with Stuvia:

Guaranteed quality through customer reviews

Guaranteed quality through customer reviews

Stuvia customers have reviewed more than 700,000 summaries. This how you know that you are buying the best documents.

Quick and easy check-out

Quick and easy check-out

You can quickly pay through credit card or Stuvia-credit for the summaries. There is no membership needed.

Focus on what matters

Focus on what matters

Your fellow students write the study notes themselves, which is why the documents are always reliable and up-to-date. This ensures you quickly get to the core!

Frequently asked questions

What do I get when I buy this document?

You get a PDF, available immediately after your purchase. The purchased document is accessible anytime, anywhere and indefinitely through your profile.

Satisfaction guarantee: how does it work?

Our satisfaction guarantee ensures that you always find a study document that suits you well. You fill out a form, and our customer service team takes care of the rest.

Who am I buying these notes from?

Stuvia is a marketplace, so you are not buying this document from us, but from seller Michelle1802. Stuvia facilitates payment to the seller.

Will I be stuck with a subscription?

No, you only buy these notes for $12.33. You're not tied to anything after your purchase.

Can Stuvia be trusted?

4.6 stars on Google & Trustpilot (+1000 reviews)

52510 documents were sold in the last 30 days

Founded in 2010, the go-to place to buy study notes for 14 years now

Start selling
$12.33  2x  sold
  • (2)
Add to cart
Added